Policy

Tackling the growing problem of overmedication

Researchers and pharmacists are seeking solutions to this serious public health problem that disproportionately affects older adults.

Are COVID-19 boosters ethical, with half the world waiting for a first shot?

Scientists debate the medical benefits of booster shots. But there’s another aspect to consider: bioethics.

Scientists must speak out against 'immune-boosting' supplements

Supplements that claim to supercharge your T-cells, make your antibodies hum and otherwise make you invincible are all bunk, and scientists should speak out more about this misinformation.

Personal chemistry: Proteomics tackles privacy concerns

Sharing raw data is an important norm for the proteomics community. But as clinical studies become more detailed, researchers may need to clamp down to protect patient privacy.

What does full FDA approval of a vaccine do if it’s already authorized for emergency use?

While emergency use authorization gets vaccines out to the public more quickly, it doesn’t skip any steps that full approval requires.

Society news briefs

Find out everything that’s been going on lately with the American Society of Biochemistry and Molecular Biology.

Steps for getting started in science policy

“Science policy is a fast-paced field. You must be able to shift quickly between priorities and projects, sometimes in response to what’s going on that week in federal policy.”

Necessary or not, COVID booster shots are probably on the horizon

In today’s pharmaceutical universe, a simple “safe and effective” determination by the FDA to approve a drug can be manipulated to sell products of questionable value. And drugmakers can profit handsomely

US travel bans: Bizarre and ruthless

Continuing travel restrictions have prevented the author and thousands of other international scholars from seeing their families for a year and a half.

ASBMB responds to proposal for new health research agency

Society recommends keeping funding for ARPA-H separate from that of other agencies and developing a unique strategic plan.

Why is the FDA funded in part by the companies it regulates?

The U.S. Food and Drug Administration receives almost half its funding from companies it regulates, such as drug and medical device makers. Is this something you should be concerned about?

ASBMB calls for changes to Title IX policy

Society urges Department of Education to revise rule created by Trump administration.